Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415372 | 0.84 | SORD (0.46) | SORDKDM4EMAPTHTTLMNA | |
| SCHEMBL7488147 | 0.83 | SORD (0.45) | SORDKDM4ESMN1; SMN2LMNA | |
| SCHEMBL7047595 | 0.78 | SORD (1.00) | SORD | |
| SCHEMBL29941725 | 0.78 | SORD (1.00) | SORD | |
| SCHEMBL6346876 | 0.78 | SORD (0.65) | SORDMEN1KMT2AKDM4EGAA | |
| SCHEMBL8780048 | 0.72 | LMNA (0.67) | SORDMEN1KMT2AKDM4EGAA | |
| SCHEMBL6406954 | 0.70 | LMNA (0.33) | SORDKMT2AKDM4ELMNA | |
| SCHEMBL13535020 | 0.69 | POLB (0.54) | SORDMEN1KMT2AKDM4EGAA | |
| SCHEMBL8780076 | 0.68 | KDM4E (0.61) | SORDMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL9729755 | 0.67 | SORD (0.49) | SORDMEN1KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894047-B2 | Triazine compounds useful as sorbitol dehydrogenase inhibitors | PFIZER INC. (US) | 2005-05-17 | — | — | US | claimed |
| US-20030004166-A1 | Novel triazine compounds useful as sorbitol dehydrogenase inhibitors | PFIZER INC. | 2003-01-02 | — | — | US | claimed |
| EP-1247809-A2 | Triazine compounds useful as sorbitol dehydrogenase inhibitors | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | claimed |
| US-6894047-B2 | Triazine compounds useful as sorbitol dehydrogenase inhibitors | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030004166-A1 | Novel triazine compounds useful as sorbitol dehydrogenase inhibitors | PFIZER INC. | 2003-01-02 | — | — | US | disclosed |
| JP-2002326987-A | NEW TRIAZINE COMPOUND USEFUL AS SORBITOL DEHYDROGENASE INHIBITOR | PFIZER PROD INC | 2002-11-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004166-A1 | Novel triazine compounds useful as sorbitol dehydrogenase inhibitors | SLC5A1, SLC5A2, ADH5 | SORD 4/4885MEN1 4816/4885KMT2A 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.